Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma

This study tests a combination approach for advanced bile duct cancer inside the liver (intrahepatic cholangiocarcinoma): freezing the tumor (cryoablation) combined with two drugs — lenvatinib (a targeted therapy) and QL1706 (a dual immunotherapy drug). This is for patients whose cancer has progressed after at least one prior treatment. **You may be eligible if...** - You are 18 or older - You have unresectable or metastatic bile duct cancer (intrahepatic cholangiocarcinoma) confirmed by biopsy - Your cancer progressed after at least one prior systemic treatment regimen **You may NOT be eligible if...** - You have never tried any prior systemic treatment - You have significant liver disease or poor health - You are pregnant or breastfeeding - You have autoimmune conditions that could be worsened by immunotherapy Talk to your doctor to see if this trial is right for you.